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Background: The number of eosinophils is increased in the mucosae of the digestive and the respiratory tracts 
in Crohn disease, even clinically quiescent. The mechanisms underlying this panmucosal eosinophilia are 
unknown. Methods: The response of blood eosinophils to various chemotactic agents was assessed in 15 patients 
with clinically quiescent Crohn disease. The results were compared with 15 healthy controls. After purification, 
eosinophils were placed in Boyden microchambers and the chemotactic effect of PAF (10-7 M), RANTES 
(50ng/ml), IL-5 (0-20ng/ml), IL-8 (0-50ng/ml), Eotaxin (0-50 ng/ml) was evaluated. The number of eosinophils 
in induced sputum of these Crohn disease patients and controls was also assessed and the correlation between 
chemotaxis and eosinophil count in induced sputum was studied.  
Results: PAF and RANTES induced a chemotactic effect both in Crohn disease patients and controls. The 
chemotactic index was significantly higher in Crohn than controls for PAF (2.09 ± 0.24 versus 1.37 ± 0.14; P < 
0.05) but not RANTES. With IL-5, IL-8 and Eotaxin, there was no detectable chemotactic effect in controls 
while in Crohn, we observed a significant dose-dependent chemotactic effect. Furthermore, with Eotaxin 50 
ng/ml, the chemotactic index was significantly higher in Crohn disease patients than controls (2.42 ± 0.18 versus 
1.56 ± 0.28; P < 0.05). A significant increase in sputum eosinophil count and a significant decrease in sputum 
macrophage count in Crohn disease were observed. However, there was no correlation between eosinophil 
chemotaxis and sputum eosinophil count in individual patients.  
Conclusion: There is an increased response of blood eosinophils to various chemotactic agents, mainly PAF and 
Eotaxin, in clinically quiescent Crohn disease. This may participate in the mucosal infiltration by eosinophils in 
this disease. 
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Crohn disease is characterized by a chronic infiltration of the bowel wall with immune and inflammatory cells 
(1). Although T lymphocytes and monocytes-macrophages are thought to play a prominent role in the 
organization of this chronic inflammation (1), the respective roles of the various cell types found in the infiltrate 
are still not known completely. Emerging evidence suggests that eosinophils may play a greater role than 
previously thought. An increased number of these cells is found not only within inflamed mucosa (2), but also 
within apparently healthy mucosa (2). Furthermore, eosinophils were also shown to infiltrate early recurrent 
lesions in the neo-terminal ileum after surgery (3, 4). Eosinophils were also present within myenteric nerves on 
the section margins of resected ileum and this infiltration was predictive of early endoscopic recurrence at the 
anastomotic site (5). In addition, we have recently described an increased number of eosinophils in the induced 
sputum of patients with Crohn disease most of whom had clinically inactive disease (6). All these data highlight 
the panmucosal infiltration with eosinophils in Crohn disease and suggest that this panmucosal eosinophilia may 
be constitutive to the disease or at least represent an early phenomenon in the development of mucosal 
inflammation. 
Theoretically, there may be many mechanisms responsible for this eosinophil mucosal infiltration. This might 
involve an increased life span of eosinophils in the mucosa, an increased production of chemotactic agents by the 
mucosa, a modification of expression of adhesion molecules in the mucosal blood vessels or finally a 
modification of the response of blood eosinophils to chemotactic agents. Several eosinophil chemotactic agents 
have been identified, including lipid mediators, small-molecular-weight peptides, growth factors and chemokines 
including members of the C-C family and the C-X-C family (7). Some of them including PAF (8), IL-5 (3, 9), 
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IL-8 (10), RANTES (11) and Eotaxin (12) have already been shown to be produced in increased amount in the 
mucosa of the digestive tract in Crohn disease. 
The aim of this study was to assess the chemotactic response of peripheral blood eosinophils to these 
chemokines in quiescent Crohn disease. 
Materials and Methods 
Patients and controls 
We studied 15 patients with Crohn disease. The diagnosis of Crohn disease was made by using standard clinical, 
radiological and endoscopic criteria. There were 11 women and 4 men. Mean age was 35 years (range, 23-57 
years). The mean time since diagnosis was 75 months (range, 7-182 months). The disease was located in the 
small bowel in 5 patients, the colon in 6 and both the colon and small bowel in 4 cases. All the patients had 
inactive disease at the time of the study (CDAI (13) <150). Three patients had a past history of extra-intestinal 
manifestation of the disease (peripheral arthritis: 2; erythema nodosum, conjunctivitis and peripheral arthritis: 1). 
No such symptom was present at the time of the study. Ten patients were treated with 5-aminosalicylic acid (2-4 
g/day), 5 were treated with azathioprine (100-175 mg/ day) and 5 had no treatment. Eight patients were smokers. 
No patient had a previous history of atopy and none of them had positive skin test for common aeroallergens 
(house dust mite, grass pollen, tree pollen, weed pollen, cat and dog dander, feathers and moulds). All the 
patients had a normal blood eosinophil count (mean (range), 1.9% (0.3%-3.2%)) and serum IgE (mean (range), 
7.2 KU/I (0.5-13.4 KU/I)). 
We also studied 15 healthy controls matched for age and sex (11 women and 4 men; mean age, 29 years (22-37 
years)). All the controls had normal blood eosinophil count, serum IgE and negative skin prick tests. 
Ethics approval was obtained for the study and all the patients and controls gave their informed consent. 
Eosinophil chemotaxis 
Eosinophils were purified from the peripheral blood by a negative immunomagnetic technique as previously 
described (14). Peripheral venous blood (45 ml) was obtained from Crohn disease patients and controls on 
heparinized tubes (10 U/ml). Blood was diluted 1/2 with an identical volume of dPBS/FCS 2% (dPBS 
(BioWhitaker, Germany): composition, g/l: KCl: 0.2; NaCl: 8, Na2HPO4: 1.15; KH2PO4: 0.2; heat inactivated 
fetal calf serum (PCS) 2% (BioWhitaker, Germany); pH 7.4). Diluted blood (30 ml) was carefully layered on top 
of 18 ml isotonic percoll (density, 1.082 g/ml) and centrifuged at 600g for 30min at room temperature. To 
prepare isotonic percoll, 100% percoll was diluted with Hepes/HBSS (HBSS (BioWhitaker, Germany): 
composition, g/l: CaCl2: 0.185; MgCl2: 0.1; MgSO2: 0.1; KCl: 0.4; NaCl: 8; Na2HPO4: 0.48; KH2PO4: 0.06; 
NaHCO3: 0.35; glucose: 1; Hepes (Boehringer, Germany) 4.8 g/l; pH 7.4) to a density of 1.082. Following 
centrifugation, the upper layer containing the polymorphonuclear cells (PMN) was carefully removed and placed 
into another tube. Red cells were lysed for 15 min at 4 °C in a buffer containing, mmol/l: NH4Cl: 155; KHCO3: 
10 and EDTA: 0.1; pH 7.4). To complete the lysis of erythrocytes, the resulting PMN were resuspended in H2O 
at 4 °C for 30 sec, and then washed twice with PBS/FCS (150 g for 5 min at 4 °C) and finally resuspended in 
500 µl PBS/FCS. One hundred µl of anti-CD 16 MACS-microbeads were added and the cells were left at 4 °C 
for 30 min to allow neutrophils to become labelled by the anti-CD 16 antibodies. To separate unlabelled 
eosinophils from magnetically labelled neutrophils, PMN were layered on top of a MACS-column type C 
(Miltenyi Biotec Inc., Sunnyvale, CA, USA) which was placed inside a strong magnetic field. Unlabelled 
eosinophils were eluted with 25 ml PBS/FCS whereas magnetically labelled neutrophils were retained on the 
column due to a strong magnetic field. This procedure resulted in about 97% pure eosinophils with neutrophils 
as contaminating cells. Viability of eosinophils was >97% as measured by trypan blue exclusion. The number of 
eosinophils isolated from 45 ml blood from normal and Crohn disease donors was 0.047 ± 0.007 × 106 cells and 
0.083 ± 0.025 × 106 cells, respectively (P = 0.24). 
Eosinophil chemotaxis was assessed by using 48-well microchambers (15). The lower and the upper chambers 
were separated by a PVP free filter the thickness of which was 8 µm. The lower chamber was filled with 25 µl of 
a suspension containing the chemotactic agent while 50 µl of an eosinophil suspension (1 × 106 cells/ml) was 
placed in the upper chamber. Both eosinophils and the several chemotactic agents were suspended in the same 
appropriate buffer (HBSS (BioWhitaker, Germany): composition, g/l: CaCl2: 0.185; MgCl2: 0.1; MgSO2: 0.1; 
KCl: 0.4; NaCl: 8; Na2HPO4: 0.48; KH2PO4: 0.06; NaHCO3: 0.35; glucose: 1; with Hepes 4.8 g/l, pH 7.4; Ca: 1; 
Mg: 1; supplemented with 0.1% bovine serum albumine (BSA, Behring, Germany)). The chemotactic agents 
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tested in the study were IL-5 at 0, 2, 20 ng/ml (Genzyme, Cambridge, UK), IL-8 at 0, 5, 50 ng/ml (Genzyme, 
Cambridge, UK), PAF at 0.1 µM (Sigma Chemical Company, St Louis, MO, USA), RANTES at 50 ng/ml 
(BioSource, California, USA) and Eotaxin at 0, 5, 50 ng/ml (PeproTech EC Ltd, London, UK). Chemotaxis 
chambers were incubated at 37 °C for 1 h. Filters were removed and non-migrated cells were scraped from the 
upper side of the filter. The filters were stained (Diff-Quick, Dade Behring Marbourg GmbH, Germany) and the 
number of migrated eosinophils per 10 high power fields was counted under light microscopy (magnification 60 
× 10). A positive chemotactic response was defined as the migration of eosinophils through the filter and 
adherence to the lower side. Each experimental condition was performed in triplicate. Results are given as the 
absolute number of cells having migrated with or without chemotactic agents or as chemotactic index (CI), 
which is defined as the ratio of the number of cells migrating through the filter in the presence and absence of 
chemotactic agents. 
Sputum induction and processing 
Sputum was induced after premedication with 400 µg inhaled salbutamol by inhalation hypertonic saline (4.5%) 
for up to 5-min periods. The whole collected sputum was processed using DTT (dithiotreitol, Sigma) 7 mM for 
30 min at room temperature and subsequently centrifuged for 10 min (400g) as previously described (16). Total 
and squamous cell counts were performed on a manual hemocytometer and samples with percentage squamous 
cell count >30% discarded. Cytospins were made from the cellular phase and stained with May-Grünwald-
Giemsa. The differential cell count was performed by counting 600 cells (excluding squamous cells). 
Statistical analysis 
Data relative to the chemotaxis were expressed as mean ± . The assessment of the chemotactic effect of the 
various agents within a group was performed by a paired t test. Comparison of the chemotactic effect between 
the groups was performed by comparing the chemotactic indexes using an unpaired t test with the Welsh 
correction. 
Cell composition of the sputum was compared between patients and controls by using the Mann-Whitney test 
and data are expressed as median and range. Correlation between sputum eosinophils and blood eosinophil 
chemotaxis was assessed by the Spearman correlation test. All values of P < 0.05 were considered to be 
significant 
Results 
The chemotactic responses of eosinophils induced by the various agents tested are shown in Table I. 
 
Table I. Response of eosinophils to various chemotactic agents. The results correspond to the mean number of 
migrated eosinophils per 10 high power fields (± ). Intragroup comparisons made using a paired t test 
 Controls (n = 15) CD patients (n = 15) 
0 M 28.21 ± 3.31 25.77 ± 3.96 PAF 
10-7M 39.2 ± 5.77** 48.67 ± 4.6** 
0 ng/ml 23.36 ± 2.45 25.85 ± 3.81 RANTES 
50 ng/ml 33.07 ± 4.11* 38.15 ± 5.58** 
0 ng/ml 27.07 ± 3.41 27.4 ± 4.34 
0.2 ng/ml 23.33 ± 3.36 34.73 ± 4.45 
2 ng/ml 34.57 ± 4.27 38.79 ± 5.41* 
IL-5 
20 ng/ml 38.73 ± 8.0 43.53 ± 5.1** 
0 ng/ml 31.14 ± 4.03 24.46 ± 3.12 
0.2 ng/ml 28.25 ± 2.66 27.45 ± 4.03 
2 ng/ml 39.5 ± 6.05 36.27 ± 5.3** 
IL-8 
20 ng/ml 34.0 ± 3.75 40.0 ± 6.02* 
0 ng/ml 31.29 ± 3.35 25.38 ± 4.58 
0.5 ng/ml 25.13 ± 2.21 26.43 ± 4.11 
5 ng/ml 29.38 ± 5.04 33.43 ± 5.83* 
Eotaxin 
50 ng/ml 44.5 ± 7.74 56.77 ± 7.51** 
* P < 0.05; ** P < 0.01. CD = Crohn disease. 
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The spontaneous migration of eosinophils was similar in patients with Crohn disease and controls (25.82 ± 2.51 
and 28.74 ± 1.95 eosinoρhils/10 fields, respectively, P > 0.05). In both controls and Crohn disease patients, PAF 
(0.1 µM) and RANTES (50 ng/ml) caused a significant chemotaxis (Table I). The PAF chemotactic index (CI) 
was significantly higher in Crohn disease than in controls (2.09 ± 0.24 versus 1.37 ± 0.14, P = 0.02) while this 
was not observed when comparing the RANTES CI between the two groups (1.54 ± 0.15 versus 1.49 ± 0.16, NS) 
(Table II). As far as IL-5, IL-8 and Eotaxin, mere was no significant chemotactic effect in controls. This 
contrasts with what we found in Crohn disease patients in whom these cytokines induced a dose-related and 
significant eosinophil chemotaxis (Table I). Furthermore, for Eotaxin at a concentration of 50 ng/ml the CI was 
significantly higher in Crohn than controls (Table II, Fig. 1). Such a significant difference was not observed for a 
lower concentration of Eotaxin nor for the various concentrations of IL-5 and IL-8 (Table II). 
 
Table II. Eosinophil chemotactic index (CI) for the various chemotactic agents tested in controls and Crohn 
disease (CD). Intergroup comparisons made using unpaired t test with Welsh correction 
 Controls (n = 15) CD patients (n = 15) 
PAF 10-7 M 1.37 ± 0.14 2.09 ± 0.24* 
RANTES 50 ng/ml 1.49 ± 0.16 1.54 ± 0.15 
0.2 ng/ml 1.07 ± 0.19 1.26 ± 0.16 
2 ng/ml 1.44 ± 0.17 1.58 ± 0.19 
IL-5 
20 ng/ml 1.58 ± 0.36 1.87 ± 0.30 
0.2 ng/ml 1.17 ± 0.21 1.26 ± 0.16 
2 ng/ml 1.51 ± 0.24 1.53 ± 0.10 
IL-8 
20 ng/ml 1.24 ± 0.14 1.74 ± 0.25 
0.5 ng/ml 0.94 ± 0.14 1.81 ± 0.53 
5 ng/ml 1.05 ± 0.15 2.27 ± 0.76 
Eotaxin 
50 ng/ml 1.56 ± 0.28 2.42 ± 0.18* 
* P < 0.05. 
 
Fig. 1. Eosinophil chemotactic index (CI) with Eotaxin in patients with Crohn disease (CD) and controls. CI is 
defined as the ratio of the number of cells that have migrated through the filter of the Boyden microchamber in 
the presence and absence of Eotaxin. Values of CI are expressed by the mean (± ) and comparison between 
Crohn disease and controls was performed by using a t test with Welsh correction. 
 
 
The sputum differential cell counts in Crohn disease patients and controls are given in Table III. The relative 
number of macrophages was decreased and the relative number of eosinophils was significantly increased in 
Crohn disease patients (P < 0.001). However, we found no significant correlation between sputum eosinophil 
count and blood eosinophil chemotaxis for the various agents tested in Crohn disease patients. 
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Table III. Sputum differential cell counts (%) in patients with Crohn disease (CD) and controls (median and 
range). Total numbers of cells were 0.89 and 1.43 × 106/g for CD patients and controls, respectively 
 CD patients (n = 12) Controls (n = 13) 
Neutrophils 39.6 (6.4-92) 28 (6.2-49.7) 
Eosinophils 1 (0-14.5)* 0.2 (0-2) 
Macrophages 31.4 (6.6-74.8)* 55.4 (43.7-85.6) 
Lymphocytes 1 (0-7.2) 1.7 (0-5) 
Epithelial cells 8 (0-70.2) 8 (0.7-25) 
* P < 0.001. 
 
Discussion 
Our work shows significant changes in eosinophil chemotaxis in patients with quiescent Crohn disease. We 
observed a significant chemotactic effect with IL-5, IL-8 and Eotaxin in Crohn disease at concentrations where 
there was no effect in controls. Furthermore, the chemotaxis assessed by the chemotactic index was significantly 
increased in Crohn disease for PAF and Eotaxin at concentrations of 10-7 M and 50 ng/ml, respectively. 
A modification of the profile of response to chemotactic agents as we found in Crohn disease, has been described 
in several diseases including asthma. In asthma, there is also an increased response to PAF (17) while the 
response to RANTES has not been shown to be substantially modified (18). Interestingly, an abnormal 
chemoattraction of eosinophil by IL-8 was also described in asthma. This result was attributed to the priming of 
eosinophils with some cytokines including IL-5 (19). However, a recent study challenged these data showing 
that in a highly purified (>99.5%) population of eosinophils, no chemoattraction was observed even after 
priming with IL-5 (20). It was suggested that previous results were due to contamination of the eosinophil 
population with neutrophils and that as little as 5% of neutrophils in the cell preparation may explain a 
chemotactic response. However, in that paper, eosinophils from asthma patients were not directly studied. This is 
in contrast with another recent study on eosinophils of asthma patients in which a purity of 98% of eosinophils 
was obtained and a dose-dependent migration was induced with IL-8 (18). Overall this migration profile in 
asthma was very similar to what we observed in our Crohn disease patients. We further found a significant 
chemotactic effect of Eotaxin on Crohn disease blood eosinophils from the concentration of 5 ng/ml. Moreover, 
at 50 ng/ml the chemotaxis induced by Eotaxin was significantly higher in Crohn disease than in controls. To our 
knowledge no such data have been clearly published so far for other diseases, including asthma. 
Several potential mechanisms may be involved in the abnormal chemotaxis we observed in Crohn disease. Some 
of them may be shared with other diseases, particularly asthma. For PAF which has already a chemotactic effect 
on normal eosinophils, an induction of expression of high-affinity binding sites on the plasma membrane may be 
proposed (17). For IL-5, IL-8 and Eotaxin, aberrant expression and modification of affinity of receptors as well 
as changes in signal transduction pathways could be involved. As far as IL-8 is concerned, fine regulation may, 
for example, depend on the type of the receptor expressed, the affinity of the receptor type B (CXCR2) being 
higher than that of type A (CXCR1) (21). For Eotaxin, no change in its receptor (CCR3) expression has been 
observed after IL-5 priming, although high levels of expression may constitutively exist in some patients 
including hypereosinophilic patients (22). These modifications in chemotactic response of eosinophils may thus 
reflect either a global abnormal activation of blood eosinophils or an increase in the proportion of a particular 
subpopulation of eosinophils in Crohn disease. All these hypotheses remain to be explored. It must also be kept 
in mind that cell populations obtained by venepuncture come mainly from the freely circulating pool and may 
not be completely representative of the whole circulating cells (including the marginated pool). Therefore, the 
changes in chemotactic response may also reflect changes in the proportion and activation of cells in these freely 
circulating and marginated pools, respectively, as well as ongoing recruitment from the bone marrow. 
The eosinophil chemotaxis is known to be particularly sensitive for cytokine priming (17, 23). Relevant blood 
concentration of several cytokines able to regulate eosinophil functions has been described in active Crohn 
disease. Proinflammatory or TH1 cytokines, such as TNFα, IL-1β, IL-6 or IFN-γ are increased in active Crohn 
disease but are close to normal in quiescent Crohn disease (24). However, increased blood concentrations of 
cytokines known to be particularly influent on eosinophil functions such as GM-CSF, IL-3 or IL-5 have not been 
described so far. It is worth noting that our patients had quiescent Crohn disease. Although chronic intestinal 
lesions are dominated by a TH1 type immune response, early recurrent lesions potentially present in still 
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clinically quiescent Crohn disease, harbour a TH2 immune profile (25). Therefore, in quiescent Crohn disease, 
the systemic cytokine environment could be closer to what is observed in asthma. The source and types of 
priming agents for eosinophils in Crohn disease has still to be clarified. On this point, a recent paper has shown 
that, beside type 2 lymphocytes, mucosal mast cells are also a significant source of IL-5 in Crohn disease (26). 
This is particularly relevant when considering the mucosal infiltration with mast cells (27) as well as their 
activation even in quiescent Crohn disease (2, 28). Such an impact of mast cells on mucosal eosinophil migration 
has already been suggested in asthma (29). Other cells able to influence eosinophil function are neutrophils. 
These cells are also increased in Crohn disease lesions and also harbour increased capacity of mucosal migration 
(30). Furthermore, an increased degranulation of these cells has been suggested even in the unaffected intestinal 
area in Crohn disease patients (31). Interestingly a recent paper showed the potential influence of neutrophil 
products such as elastase on eosinophil activation and degranulation (32). 
In accordance with our previous results (6), we found a significant increase in eosinophil count and a decreased 
macrophage count in sputum of patients with Crohn disease. The magnitude of sputum eosinophilia was 
however in the present sample less spectacular than in our previous work. Despite the coupled increase in 
eosinophil chemotaxis to various chemokines and in mucosal infiltration with eosinophils in Crohn disease, we 
did not observe a strict correlation between chemotactic response to the various agents tested and sputum 
eosinophils. This may reflect the complexity of the mechanisms determining mucosal eosinophil infiltration. 
This is a multifactorial phenomenon in which the magnitude of the chemotactic response of circulating 
eosinophils to chemokines is only one of the factors involved beside the degree of expression of adhesion 
molecules, production of chemotactic agents by the mucosa and local survival of eosinophils. 
Several studies have already shown an increased production of PAF (8), RANTES (11), IL-5 (3, 9), IL-8 (10) 
and Eotaxin (12) in the intestinal mucosa of patients with Crohn disease. Combined with the increased 
chemotactic response toward the agents tested here, this increased production may contribute to the recruitment 
of mucosal eosinophils. Interestingly, a recent study showed different profiles of production of chemotactic 
agents in early recurrent lesions of Crohn disease as compared to chronic lesions (Desreumaux, personal 
communication). The same group had already showed that these early lesions had rather a TH2 immune profile 
as opposed to the TH1 immune profile of the chronic lesions and that the eosinophils were also relatively more 
numerous in those early lesions (25). They recently showed significantly higher levels of Eotaxin and RANTES 
in early compared to chronic lesions. On the opposite, IL-8 was significantly higher in chronic than early lesions. 
Overall, combining these data with ours, the role of Eotaxin that had the most increased chemotactic effect on 
eosinophils in our study, seems to be prominent in the recruitment of eosinophils in the mucosa of patients with 
Crohn disease, particularly in early lesions. 
However, important questions remain unsolved and would justify further studies. Among them, the potential 
variation of eosinophil chemotactic response and mucosal migration according to the activity of the disease and 
the chronicity of the lesions as well as the possible recruitment of a particular subtype of eosinophils 
characterized by specific immune or inflammatory function are relevant questions for the understanding of the 
role of mucosal eosinophilia in Crohn disease. The constitutive or rather secondary nature of this abnormal 
eosinophil chemotactic response is also an important point to solve. From this point of view, the study of 
unaffected siblings would represent an elegant approach. 
In conclusion, we have shown an abnormal chemotactic response of blood eosinophils to PAF, IL-5, IL-8 and 
particularly Eotaxin in clinically quiescent Crohn disease. However, the specific impact of this chemotactic 
response on the magnitude and specificity of eosinophil mucosal recruitment, which is a complex phenomenon, 
remains to be clarified. 
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